AVL9 Antibodies

Late secretory pathway protein AVL9 homolog (AVL9)

Functions in cell migration. .

Gene Information

Human
Gene Name:	AVL9
Uniprot:	Q8NBF6
Entrez:	23080

Family

Belongs to:
AVL9 family

Alternative Names

AVL9 homolog (S. cerevisiase)

Molecular Weight

Mass (kDA):
71.947 kDA

Genomic Context

Human
Location:	7p14.3
Sequence:	7; NC_000007.14 (32495489..32588726)

Subcellular Localizations

Recycling endosome. Membrane; Single-pass membrane protein.

Pathways

• Transport
• Drug Resistance
• Secretory Pathway
• Cell Proliferation
• Cell Migration
• Endocytic Recycling

• Secretion

PTMs

• Methylation

• Phosphoprotein

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/AVL9

Best Uses Of The AVL9 Marker From Boster Bio

The AVL9 marker can be used in many ways. Boster offers high-affinity primary antibodies, ELISA kits, and AVL9 markers. Here are some examples. Let's take an in-depth look at each. You may be surprised at all the uses for AVL9.

Boster offers primary antibodies with high affinity

Boster Anti–KHDRBS2 antibody has a high affinity, human IgG1 conjugated protein antibody. It reacts with AVL9 marker. Boster supplies this antibody in both 100-ul Liquid form and in diluted form for IP/WB and IHC applications. These antibodies are tested in IHC, WB, and IP, and are provided in a convenient, low-cost Liquid format for ease of use.

Primary antibodies are immunoglobulins whose target antigens can only be bound to them. The quality of primary antibodies is primarily determined by their specificity and affinity. Higher affinity is better, but lower specificity indicates greater binding to non-targeted antibodies. High-affinity antibodies are useful for the detection, purification and measurement of the antigen in question.

Boster offers ELISA kits

The Boster Bio AVL9 ELISA kit is designed to measure the presence of AVL9 in various biological samples. These kits use rabbit and mouse antibodies to detect AVL9. The Boster Bio AVL9 ELISA kit can be stored for one year at -20°C and is reconstituted in a solution of 50% glycerol, 0.2% Na2HPO4. It can be used for a variety of applications and has no cross-reactivity with other proteins.

Boster Bio Picokine(r), Fast ELISA kits contains both the biotinylated and capture antibodies. These two antibodies form a sandwich that binds to target molecules in one step. Then, the Avidin-Biotin-Peroxidase Complex is added, which acts as the TMB substrate and yields a blue product proportional to the amount of target analyte. This kit can be used to analyze a variety of target analytes and has been validated on a wide range biologic samples.

Boster sells AVL9 markers

Boster offers AVL9 marker testing as part of its extensive range of genomic testing. The markers' levels of expression have been analyzed by several databases, such as LinkedOmics cBioportal or GEO. SurvExpress was used to evaluate the gene's expression for correlation with clinical survival prognosis. LinkedOmics and cBioPortal were used to identify markers for protein-protein interaction networks analysis, signal pathway enrichment and gene ontology.

AVL9 is located on human chromosome 7.14:32,495,489-32,588,726. The gene has a length of 111,980 nanometers and is located on chromosome 11.14. It is associated to tumorigenesis and plays a significant role in the development of and progression from cancer. It is positively correlated to RNF216, KIAA1147 and EPDR1.

AVL9 was initially identified in yeast as an exocytosis genes. However, it was later discovered to play an important part in cell polarity, and migration. Liang et.al. reported it's role in tumorigenesis. Liang et. al. reported that MiR203a-3p suppressed NSCLC cancer cell proliferation and migration when overexpressed with AVL9. Moreover, the gene's direct target miR-497-5p promoted AVL9 expression in nonsmall-cell lung cancer.

Despite its importance in cancers of the human body, its exact function remains a mystery. Although it was associated with poor prognosis in patients with colorectal carcinoma, the exact mechanism is still unclear. Overexpression or knockdown of AVL9 produced the opposite effect. Cell migration was promoted by AVL9. AVL9 also inhibited EGFR's expression, which impeded cells from migrating in a way that promoted tumorigenesis.

CRC has a high level of AVL9 expression. In addition, AVL9 is associated with high-grade CRC tumors. People with high levels are also more likely to die from this protein. Despite its relatively recent introduction, more large-scale studies are required to validate AVL9's advantages in early diagnosis of CRC. With further validation, the markers could serve as a liquid biopsy biomarker and help physicians better evaluate treatment effects and chemotherapy-acquired drug resistance.